Enalare Therapeutics is developing ENA-001, a novel therapeutic agent designed to stimulate breathing in patients experiencing acute respiratory depression due to drug overdoses, post-operative complications, or apnea of prematurity. This new chemical entity aims to provide effective treatment options for healthcare providers managing life-threatening respiratory conditions.
Funding
$23.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BAFounders
Product
Problem
Acute respiratory depression, caused by drug overdoses, post-operative complications, or apnea of prematurity, leads to life-threatening conditions requiring immediate intervention. Current treatment options may be inadequate or have limitations in various clinical settings. The escalating drug overdose epidemic and other respiratory-related emergencies highlight the urgent need for novel therapeutic interventions.
Solution
Enalare Therapeutics is developing ENA-001, a novel, patent-protected new chemical entity (NCE) designed to stimulate breathing in patients experiencing acute respiratory depression. ENA-001 offers a novel mechanism-of-action with demonstrated safety and efficacy, providing healthcare providers with a new treatment option for managing life-threatening respiratory conditions. The therapeutic aims to address respiratory depression in multiple settings, including drug overdoses, post-operative complications, and apnea of prematurity. By stimulating respiration, ENA-001 has the potential to improve patient outcomes and reduce the burden on the healthcare system associated with acute respiratory emergencies. Clinical trials for ENA-001 are ongoing.
Target Audience
The primary target audience includes healthcare providers, emergency responders, and caregivers who manage patients experiencing acute respiratory depression due to drug overdoses, post-operative complications, or apnea of prematurity.
Features
- Novel chemical entity (NCE) with a unique mechanism-of-action for stimulating respiration
- Designed to address acute respiratory depression from various causes
- Potential applicability in multiple clinical settings, including emergency rooms and neonatal care units